{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:26:35Z","timestamp":1791620795636,"version":"4.3.4"},"reference-count":42,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibromodulin (FMOD) was shown to be highly overexpressed in chronic lymphocytic leukemia (CLL) cells compared with normal B lymphocytes by gene expression profiling. Therefore FMOD might serve as potential tumor-associated antigen (TAA) in CLL, enabling expansion of FMOD-specific T cells. In CLL samples derived from 16 different patients, high expression of FMOD by real-time reverse transcriptase\u2013polymerase chain reaction (RT-PCR) was detectable in contrast to normal B lymphocytes. We used unpulsed native CLL cells and CD40 ligand (CD40L)\u2013stimulated CLL cells as antigen-presenting cells (APCs) to expand autologous T cells from 13 patients. The number of T cells during 4 weeks of in vitro culture increased 2- to 3.5-fold and the number of T cells recognizing FMOD peptides bound to HLA-A2 dimers increased 10-fold. The expanded T cells also were able to secrete interferon-\u03b3 (IFN-\u03b3) upon recognition of the antigen demonstrated by IFN-\u03b3 ELISPOT assays. T cells not only recognized HLA-A2\u2013binding FMOD peptides presented by transporter-associated with antigen-processing (TAP)\u2013deficient T2 cells, but also FMOD overexpressing autologous CLL cells in an HLA-A2\u2013restricted manner. In summary, FMOD was shown for the first time to be naturally processed and presented as TAA in primary CLL cells, enabling the expansion of autologous tumor-specific T cells.<\/jats:p>","DOI":"10.1182\/blood-2004-04-1233","type":"journal-article","created":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:23:53Z","timestamp":1097195033000},"page":"1566-1573","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":59,"title":["Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes"],"prefix":"10.1182","volume":"105","author":[{"given":"Christine","family":"Mayr","sequence":"first","affiliation":[{"name":"From the Klinische Kooperationsgruppe (KKG) Gene Therapy, Munich, Germany, GSF-National Research Center for Environment and Health; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich; Medical Clinic I, University of Cologne, Cologne; Clinical Molecular Biology and Tumor Genetics, GSF-National Research Center for Environment and Health, Munich, and the Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Bund","sequence":"additional","affiliation":[{"name":"From the Klinische Kooperationsgruppe (KKG) Gene Therapy, Munich, Germany, GSF-National Research Center for Environment and Health; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich; Medical Clinic I, University of Cologne, Cologne; Clinical Molecular Biology and Tumor Genetics, GSF-National Research Center for Environment and Health, Munich, and the Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlee","sequence":"additional","affiliation":[{"name":"From the Klinische Kooperationsgruppe (KKG) Gene Therapy, Munich, Germany, GSF-National Research Center for Environment and Health; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich; Medical Clinic I, University of Cologne, Cologne; Clinical Molecular Biology and Tumor Genetics, GSF-National Research Center for Environment and Health, Munich, and the Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Moosmann","sequence":"additional","affiliation":[{"name":"From the Klinische Kooperationsgruppe (KKG) Gene Therapy, Munich, Germany, GSF-National Research Center for Environment and Health; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich; Medical Clinic I, University of Cologne, Cologne; Clinical Molecular Biology and Tumor Genetics, GSF-National Research Center for Environment and Health, Munich, and the Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kofler","sequence":"additional","affiliation":[{"name":"From the Klinische Kooperationsgruppe (KKG) Gene Therapy, Munich, Germany, GSF-National Research Center for Environment and Health; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich; Medical Clinic I, University of Cologne, Cologne; Clinical Molecular Biology and Tumor Genetics, GSF-National Research Center for Environment and Health, Munich, and the Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"From the Klinische Kooperationsgruppe (KKG) Gene Therapy, Munich, Germany, GSF-National Research Center for Environment and Health; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich; Medical Clinic I, University of Cologne, Cologne; Clinical Molecular Biology and Tumor Genetics, GSF-National Research Center for Environment and Health, Munich, and the Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens-Martin","family":"Wendtner","sequence":"additional","affiliation":[{"name":"From the Klinische Kooperationsgruppe (KKG) Gene Therapy, Munich, Germany, GSF-National Research Center for Environment and Health; Medical Clinic III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, Munich; Medical Clinic I, University of Cologne, Cologne; Clinical Molecular Biology and Tumor Genetics, GSF-National Research Center for Environment and Health, Munich, and the Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217521731500_REF1","doi-asserted-by":"crossref","unstructured":"Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997;18: 175-182.","DOI":"10.1016\/S0167-5699(97)84664-6"},{"key":"2020021217521731500_REF2","doi-asserted-by":"crossref","unstructured":"Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 1997;9: 684-693.","DOI":"10.1016\/S0952-7915(97)80050-7"},{"key":"2020021217521731500_REF3","doi-asserted-by":"crossref","unstructured":"Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10: 673-679.","DOI":"10.1016\/S1074-7613(00)80066-7"},{"key":"2020021217521731500_REF4","doi-asserted-by":"crossref","unstructured":"Oldberg A, Antonsson P, Lindblom K, Heinegard D. A collagen-binding 59-kd protein (fibromodulin) is structurally related to the small interstitial proteoglycans PG-S1 and PG-S2 (decorin). EMBO J. 1989;8: 2601-2604.","DOI":"10.1002\/j.1460-2075.1989.tb08399.x"},{"key":"2020021217521731500_REF5","doi-asserted-by":"crossref","unstructured":"Hedbom E, Heinegard D. Interaction of a 59-kDa connective tissue matrix protein with collagen I and collagen II. J Biol Chem. 1989;264: 6898-6905.","DOI":"10.1016\/S0021-9258(18)83516-5"},{"key":"2020021217521731500_REF6","doi-asserted-by":"crossref","unstructured":"Hildebrand A, Romaris M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J. 1994;302: 527-534.","DOI":"10.1042\/bj3020527"},{"key":"2020021217521731500_REF7","doi-asserted-by":"crossref","unstructured":"Soo C, Hu FY, Zhang X, et al. Differential expression of fibromodulin, a transforming growth factor-beta modulator, in fetal skin development and scarless repair. Am J Pathol. 2000;157: 423-433.","DOI":"10.1016\/S0002-9440(10)64555-5"},{"key":"2020021217521731500_REF8","doi-asserted-by":"crossref","unstructured":"Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194: 1625-1638.","DOI":"10.1084\/jem.194.11.1625"},{"key":"2020021217521731500_REF9","unstructured":"Jelinek DF, Tschumper RC, Stolovitzky GA, et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res. 2003;1: 346-361."},{"key":"2020021217521731500_REF10","doi-asserted-by":"crossref","unstructured":"Vallat L, Magdele\u0301nat H, Merle-Be\u0301ral H, et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood. 2003;101: 4598-4606.","DOI":"10.1182\/blood-2002-06-1743"},{"key":"2020021217521731500_REF11","unstructured":"Mikaelsson E, Jeddi-Tehrani M, O\u0308sterborg A, Shokri F, Mellstedt H, Rabbani H. Fibromodulin\u2014a novel tumor associated antigen exclusively expressed in tumor B-cells from patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Lymphoma [abstract]. 2003; 44(suppl 2): 21."},{"key":"2020021217521731500_REF12","doi-asserted-by":"crossref","unstructured":"Cheson B, Bennett JM, Grever M, et al. National Cancer Institute\u2013sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87: 4990-4997.","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"2020021217521731500_REF13","doi-asserted-by":"crossref","unstructured":"Schlee M, Krug T, Gires O, et al. Identification of Epstein-Barr Virus (EBV) nuclear antigen 2 (EBNA2) target protein by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV. J Virol. 2004;78: 3941-3952.","DOI":"10.1128\/JVI.78.8.3941-3952.2004"},{"key":"2020021217521731500_REF14","doi-asserted-by":"crossref","unstructured":"Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: 1st listing. Immunogenetics. 1995;41: 178-228.","DOI":"10.1007\/BF00172063"},{"key":"2020021217521731500_REF15","doi-asserted-by":"crossref","unstructured":"Van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994;24: 3038-3043.","DOI":"10.1002\/eji.1830241218"},{"key":"2020021217521731500_REF16","doi-asserted-by":"crossref","unstructured":"Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia (B-CLL) cells for tumor immunotherapy: stimulation of allogeneic versus autologous T-cells generates different types of effector cells. Blood. 1999;93: 1992-2002.","DOI":"10.1182\/blood.V93.6.1992.406k23_1992_2002"},{"key":"2020021217521731500_REF17","doi-asserted-by":"crossref","unstructured":"Garrone P, Neidhardt EM, Garcia E, Galibert L, von Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 1995;182: 1265-1273.","DOI":"10.1084\/jem.182.5.1265"},{"key":"2020021217521731500_REF18","doi-asserted-by":"crossref","unstructured":"Tan LC, Gudgeon N, Annels NE, et al. A reevaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162: 1827-1835.","DOI":"10.4049\/jimmunol.162.3.1827"},{"key":"2020021217521731500_REF19","doi-asserted-by":"crossref","unstructured":"Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol. 2000;165: 6229-6234.","DOI":"10.4049\/jimmunol.165.11.6229"},{"key":"2020021217521731500_REF20","doi-asserted-by":"crossref","unstructured":"Wallin JJ, Liang L, Bakardjiev A, Sha WC. Enhancement of CD8+ T cell responses by ICOS\/B7h costimulation. J Immunol. 2001;167: 132-139.","DOI":"10.4049\/jimmunol.167.1.132"},{"key":"2020021217521731500_","doi-asserted-by":"crossref","unstructured":"Zuberek K, Ling V, Wu P, et al. Comparable in vivo efficacy of CD28\/B7, ICOS\/GL50, and ICOS\/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. Cell Immunol. 2003;225: 53-63.","DOI":"10.1016\/j.cellimm.2003.09.002"},{"key":"2020021217521731500_","doi-asserted-by":"crossref","unstructured":"Palma C, Binaschi M, Bigioni M, Maggi CA, Goso C. CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival. Int J Cancer. 2004;108: 390-398.","DOI":"10.1002\/ijc.11574"},{"key":"2020021217521731500_","doi-asserted-by":"crossref","unstructured":"Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995;85: 3556-3565.","DOI":"10.1182\/blood.V85.12.3556.bloodjournal85123556"},{"key":"2020021217521731500_","doi-asserted-by":"crossref","unstructured":"Bristol LA, Sakaguchi K, Appella E, Doyle D, Takacs L. Thymocyte costimulation antigen is CD26 (dipeptidyl peptidase IV): costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26. J Immunol. 1992;149: 367-372.","DOI":"10.4049\/jimmunol.149.2.367"},{"key":"2020021217521731500_","doi-asserted-by":"crossref","unstructured":"Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires didipeitdyl peptidase IV enzymatic acitivity. Proc Natl Acad Sci U S A. 1993;90: 4586-4590.","DOI":"10.1073\/pnas.90.10.4586"},{"key":"2020021217521731500_REF26","doi-asserted-by":"crossref","unstructured":"Bauvois B, De Meester I, Dumont J, Rouillard D, Zhao HX, Bosmans E. Constitutive expression of CD26\/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. Br J Cancer. 1999;79: 1042-1048.","DOI":"10.1038\/sj.bjc.6690167"},{"key":"2020021217521731500_REF27","doi-asserted-by":"crossref","unstructured":"Benoist C, Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol. 1990;8: 681-715.","DOI":"10.1146\/annurev.iy.08.040190.003341"},{"key":"2020021217521731500_REF28","doi-asserted-by":"crossref","unstructured":"Dutoit V, Guillaume P, Ayyoub M, Hesdorffer CS, Luescher IF, Valmori D. Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC\/TCR dissociation rate. J Immunol. 2003;170: 5110-5117.","DOI":"10.4049\/jimmunol.170.10.5110"},{"key":"2020021217521731500_REF29","doi-asserted-by":"crossref","unstructured":"Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation\/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol. 2001;112: 959-964.","DOI":"10.1046\/j.1365-2141.2001.02672.x"},{"key":"2020021217521731500_REF30","doi-asserted-by":"crossref","unstructured":"Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100: 2757-2765.","DOI":"10.1172\/JCI119822"},{"key":"2020021217521731500_REF31","doi-asserted-by":"crossref","unstructured":"Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101: 1133-1141.","DOI":"10.1172\/JCI1472"},{"key":"2020021217521731500_REF32","doi-asserted-by":"crossref","unstructured":"Wendtner CM, Kofler DM, Theiss HD, et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood. 2002;100: 1655-1661.","DOI":"10.1182\/blood.V100.5.1655.h81702001655_1655_1661"},{"key":"2020021217521731500_REF33","doi-asserted-by":"crossref","unstructured":"Chatterjee M, Barcos M, Han T, Liu XL, Bernstein Z, Foon KA. Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma. Blood. 1990;76: 1825-1829.","DOI":"10.1182\/blood.V76.9.1825.1825"},{"key":"2020021217521731500_REF34","doi-asserted-by":"crossref","unstructured":"Kwak LW. Translational development of active immunotherapy for hematologic malignancies. Semin Oncol. 2003;30: 17-22.","DOI":"10.1016\/S0093-7754(03)00232-X"},{"key":"2020021217521731500_REF35","doi-asserted-by":"crossref","unstructured":"Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest. 2004;113: 1498-1510.","DOI":"10.1172\/JCI20312"},{"key":"2020021217521731500_REF36","doi-asserted-by":"crossref","unstructured":"Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med. 2000;6: 667-672.","DOI":"10.1038\/76243"},{"key":"2020021217521731500_REF37","unstructured":"Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61: 869-872."},{"key":"2020021217521731500_","unstructured":"Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I\u2013restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61: 5964-5968."},{"key":"2020021217521731500_REF39","doi-asserted-by":"crossref","unstructured":"Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003; 102: 571-576.","DOI":"10.1182\/blood-2002-08-2554"},{"key":"2020021217521731500_REF40","doi-asserted-by":"crossref","unstructured":"Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6: 597-641.","DOI":"10.1146\/annurev.cb.06.110190.003121"},{"key":"2020021217521731500_","unstructured":"Alexandrow MG, Moses HL. Transforming growth factor-beta and cell cycle regulation. Cancer Res. 1995;55: 1452-1457."},{"key":"2020021217521731500_REF42","doi-asserted-by":"crossref","unstructured":"Lagneaux L, Delforge A, Bron D, Massy M, Bernier M, Stryckmans P. Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-\u03b2 receptors. Br J Haematol. 1997;97: 612-620.","DOI":"10.1046\/j.1365-2141.1997.792715.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/4\/1566\/1706391\/zh800405001566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/4\/1566\/1706391\/zh800405001566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T13:31:41Z","timestamp":1682775101000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/4\/1566\/20342\/Fibromodulin-as-a-novel-tumorassociated-antigen"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,15]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-04-1233","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,15]]}}}